Novoteris, LLC., Medical Device and Pharmaceutical Product Innovators, Receives Orphan Drug Designation for Nitric Oxide for the Treatment of Cystic Fibrosis.

Garden Grove, CA—December 18, 2013 (eReleases):  Novoteris, LLC. A clinical stage medical device and pharmaceutical developer focused on innovative applications for nitric oxide gas where it can be applied for unmet medical needs, announced today that the European Commission, Health & Consumers Directorate-General Medicinal products – authorizations, EMA, has granted it orphan drug designation for